Preclinical characterization of JAK1/JAK2 inhibitors for treatment of type 1 diabetes

被引：0
|
作者：
Scott, N. A. [1 ,2 ]
Trivedi, P. M. [1 ,2 ]
Graham, K. L. [1 ,2 ]
Fynch, S. [1 ]
Jenkins, M. R. [3 ]
Kay, T. W. [1 ,2 ]
Thomas, H. E. [1 ,2 ]
机构：
[1] St Vincents Inst, Immunol & Diabet Unit, Fitzroy, Vic, Australia
[2] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia
[3] Peter MacCallum Canc Ctr, Canc Immunol Res, East Melbourne, Australia
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2016年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
3795
引用
收藏
页码：361 / 361
页数：1
相关论文
共 50 条
  • [21] The JAK1/JAK2 Inhibitor Ruxolitinib Substantially Affects NK Cell Biology
    Schoenberg, Kathrin
    Rudolph, Janna
    Cornez, Isabelle
    Brossart, Peter
    Wolf, Dominik
    BLOOD, 2013, 122 (21)
  • [22] Variants in the JAK1 and JAK2 genes in the risk and prognosis of patients with cutaneous melanoma
    Carvalho, B. F.
    Gomez, G. V. B.
    Lourenco, G. J.
    Moraes, A. M. D.
    Lima, C. S. Passos
    ANNALS OF ONCOLOGY, 2019, 30 : 14 - 14
  • [23] Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma
    Nilsson, Magnus
    Rhedin, Magdalena
    Hendrickx, Ramon
    Berglund, Susanne
    Piras, Antonio
    Blomgran, Parmis
    Cavallin, Anders
    Collins, Mia
    Dahl, Goran
    Dekkak, Bilel
    Ericsson, Therese
    Hagberg, Niklas
    Holmberg, Ann Aurell
    Leffler, Agnes
    Lundqvist, Anders J.
    Markou, Thomais
    Pinkerton, James
    Ronnblom, Lars
    Siu, Stacey
    Taylor, Vanessa
    Wennberg, Tiiu
    Zervas, Dimitrios
    Laurence, Arian D. J.
    Mitra, Suman
    Belvisi, Maria G.
    Birrell, Mark
    Borde, Annika
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 2901 - 2917
  • [24] Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
    Williams, Neal K.
    Bamert, Rebecca S.
    Patel, Onisha
    Wang, Christina
    Walden, Patricia M.
    Wilks, Andrew F.
    Fantino, Emmanuelle
    Rossjohn, Jamie
    Lucet, Isabelle S.
    JOURNAL OF MOLECULAR BIOLOGY, 2009, 387 (01) : 219 - 232
  • [25] Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis
    Pardanani, Animesh
    Gotlib, Jason
    Gupta, Vikas
    Roberts, Andrew W.
    Wadleigh, Martha
    Sirhan, Shireen
    Bavisotto, Linda M.
    Kawashima, Jun
    Lee, Peter
    Kowalski, Mark
    Deng, Wei
    Niforos, Demi
    Tefferi, Ayalew
    BLOOD, 2013, 122 (21)
  • [26] Discovery of INCB018424: A potent and selective JAK1/JAK2 inhibitor for the treatment of myeloproliferative neoplasms
    Rodgers, James D.
    Fridman, Jordan S.
    Shepard, S.
    Maduskuie, T. P.
    Arvanitis, A. G.
    Wang, H.
    Shao, L.
    Folmer, B.
    Falahatpisheh, N.
    Rafalski, M.
    Storace, L.
    Jalluri, R. K.
    Vaddi, K.
    Haley, P. J.
    Burn, T. C.
    Rupar, M.
    Liu, P. C.
    Covington, M. B.
    Caulder, E.
    Li, J.
    Waeltz, P.
    Margulis, A.
    Wynn, R.
    Becker-Pasha, M.
    Li, Y.
    Lo, Y.
    Thomas, B.
    Hollis, G.
    Favata, M. F.
    Wen, X.
    Kelly, J.
    Solomon, K.
    Scherle, P. A.
    Shi, J.
    Yeleswaram, S.
    Newton, R. C.
    Friedman, S. M.
    Metcalf, B.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [27] Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
    Pardanani, Animesh
    Gotlib, Jason
    Gupta, Vikas
    Roberts, Andrew W.
    Wadleigh, Martha
    Sirhan, Shireen
    Bavisotto, Linda M.
    Kawashima, Jun
    Kowalski, Mark
    Tefferi, Ayalew
    BLOOD, 2012, 120 (21)
  • [28] JAK1/2 INHIBITION IN THE TREATMENT OF CGVHD
    Alchalby, H.
    Stuebig, T.
    Ayuk, F.
    Kroeger, N.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S539 - S540
  • [29] Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3
    Malerich, Jeremiah P.
    Lam, Jennifer S.
    Hart, Barry
    Fine, Richard M.
    Klebansky, Boris
    Tanga, Mary J.
    D'Andrea, Annalisa
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (24) : 7454 - 7457
  • [30] JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment
    Zhang, Yun
    Liang, Ruifang
    Chen, Chih-Wei
    Mallano, Tatjana
    Dees, Clara
    Distler, Alfiya
    Reich, Adam
    Bergmann, Christina
    Ramming, Andreas
    Gelse, Kolja
    Mielenz, Dirk
    Distler, Oliver
    Schett, Georg
    Distler, Joerg H. W.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (08) : 1467 - 1475
12345